 "NPPA extends price caps to 39 more medicines")
The National Pharmaceutical Pricing Authority (NPPA) has extended price caps to 39 more medicines ranging from commonly used diabetes drugs to antibiotics, in the government's latest effort to improve affordability of medicines.
The move impacts multinational drugmakers, like Abbott Laboratories and GlaxoSmithKline Plc , and a number of local firms, including Lupin Ltd , Cadila Healthcare Ltd and Ipca Ltd , all of whom sell drugs added to the list.
A notice posted on the NPPA website late on Wednesday detailed the 39 new drugs, which extend a price control list that already includes more than 652 medicines.
New drugs added to the list include commonly used antibiotics such as azithromycin, combinations of metformin for diabetes, as well as the anti-emetic domperidone.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app